Additional file 1 of Maternal immune-mediated conditions and ADHD risk in offspring

Additional file 1: This file includes details on exposure data (Table S1), covariate selection and associations between covariates and between covariates and exposure variables (Tables S2 and S3), covariates included in different Dagitty models (DAGs) (Table S4), DAGs that forms the basis of the minimal sufficient adjustment sets of covariates for each of the exposure categories (Figs. S1–S10), and information regarding the handling of missing data. In addition, this contains descriptive information on exposed and unexposed cases as well as missing data for the main analyses (Tables S5 and S6). Additional analyses conducted on unimputed data are also included in the file (Table S7), as well as more detailed statistics from the negative control analyses (Table S8) and results from the sensitivity analyses (Tables S9 and S10). Table S1 Health conditions reported in questionnaires at specific times during pregnancy. Table S2 Associations between considered covariates and exposure variables. Table S3 Associations between covariates. Table S4 Covariates included in Dagitty models and minimum sufficient adjustment sets for each specific analysis. Table S5 Descriptive statistics for dataset analyzing maternal immune-mediated conditions in pregnancy and ADHD in offspring with Cox proportional hazards. Table S6 Descriptive statistics for dataset analyzing maternal diabetes in pregnancy and ADHD in offspring with Cox proportional hazards. Table S7 Associations between maternal immune-mediated conditions during pregnancy and ADHD in offspring examined with Cox proportional hazard analyses. Table S8 Associations between maternal gestational immune-mediated conditions and offspring ADHD diagnoses compared with the associations with paternal immune-mediated conditions, mutually adjusted for each other. Table S9 Sensitivity analyses for use of folic acid between 4 weeks before pregnancy and 8 weeks of gestation. Table S10 Analyses stratified by the specific immune-mediated condition assessing whether medications alters the risk of developing ADHD among, e.g., asthmatics. Fig. S1 Directed acyclic graph (DAG) for covariate selection in analyses on prenatal exposure to asthma, allergy, and atopic conditions and ADHD risk. Fig. S2 DAG for covariate selection in analyses on prenatal exposure to autoimmune and inflammatory conditions and ADHD risk. Fig. S3 DAG for covariate selection in analyses on prenatal exposure to asthma and ADHD risk. Fig. S4 DAG for covariate selection in analyses on prenatal exposure to allergies and ADHD risk. Fig. S5 DAG for covariate selection in analyses on prenatal exposure to eczema and ADHD risk. Fig. S6 DAG for covariate selection in analyses on prenatal exposure to urticaria/hives and ADHD risk. Fig. S7 DAG for covariate selection in analyses on prenatal exposure to psoriasis and ADHD risk. Fig. S8 DAG for covariate selection in analyses on prenatal exposure to gastrointestinal conditions and ADHD risk. Fig. S9 DAG for covariate selection in analyses on prenatal exposure to rheumatologic musculoskeletal conditions and ADHD risk. Fig. S10 DAG for covariate selection in analyses on prenatal exposure to endocrine conditions and ADHD risk [103–105].